Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ezetimibe + rosuvastatin (Daewoong Pharmaceutical)
- Development stage
- Phase 4
- Lead developer
- Daewoong Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Crezet is a fixed-dose combination (FDC) tablet containing ezetimibe and rosuvastatin calcium, developed by Daewoong Pharmaceutical for the management of dyslipidemia. Rosuvastatin is an HMG-CoA reductase inhibitor that lowers cholesterol by inhibiting its synthesis in the liver and increasing the number of LDL receptors on the cell surface. Ezetimibe is a selective cholesterol absorption inhibitor that targets the Niemann-Pick C1-like 1 (NPC1L1) protein in the small intestine, reducing the delivery of intestinal cholesterol to the liver. By combining these two mechanisms, Crezet provides a dual approach to lowering low-density lipoprotein cholesterol (LDL-C) levels more effectively than either agent alone. It is primarily marketed in South Korea for patients with primary hypercholesterolemia or mixed dyslipidemia.
- Brand names
- Crezet
- Other names
- ezetimibe/rosuvastatinezetimibe + rosuvastatin calcium
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)NPC1L1 (Niemann-pick C1-Like 1 transporter)
Beyond the preview
Go deeper on ezetimibe + rosuvastatin (Daewoong Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ezetimibe + rosuvastatin (Daewoong Pharmaceutical).